MicroUDxTM: a Rapid Diagnostic Tool That Will Prevent Death and Disability From Common Infections

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-08-01

Study Completion Date

2023-10-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background \& Rational:

Antibiotics are a major underpinning of modern medicine. The global rise of antimicrobial resistant (AMR) organisms is a serious world health problem. With few new antimicrobial drugs on the horizon, it is imperative that we develop novel approaches to extend the service life of our existing drugs. AMR is a complex problem that is being driven by a wide range of factors. More than half of the antibiotics prescribed have no medical benefit, and outpatient visits for uncomplicated urinary tract infections (UTIs) are a major contributor to this problem. Recent studies have shown that nearly half of people treated for UTIs receive the wrong frontline drug and in 75% of patients, the duration of therapy is inappropriate. Limitations in the current diagnostic technology make it impossible to identify UTI pathogens and measure their antibiotic sensitivities during the short out-patient clinical visits that are typical for most UTI patients. These circumstances result in the inappropriate use of stronger than necessary or inappropriate antimicrobials. The aim of this study is to develop and evaluate a system that can detect bacteria in urine and find the best antibiotic in under 4 hours, thus enabling a rapid diagnosis and use of the most appropriate and cost-effective antimicrobial agent for the agent detected.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diagnosis of Subclinical Urinary Tract Infections Using Advanced Microbiome Survey Techniques in High Risk Trauma Patients

NCT01834391

Urinary Tract Infection

COMPLETED

Rapid Urinary Tract Infection Diagnosis and Real-time Antimicrobial Stewardship Decision Support

NCT03256825

Urinary Tract Infections

COMPLETED NA

Dipsticks and Microscopy to Reduce Antibiotic Use in Women's Urinary Tract Infections: a Pilot Trial (MicUTI)

NCT05667207

Cystitis Acute Antibiotic Resistant Infection Medication Adherence +2 more

COMPLETED NA

DIagnoSing Care hOme UTI Study

NCT05880329

Urinary Tract Infections

RECRUITING

Analysis of Bacterial Multidrug Tolerance in Patients Prone to Urinary Tract Infections

NCT06724588

Patients with Recurrent or Chronic UTIs Patients with a Suprapubic Catheter Patients with a Nephrostomy Catheter

ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Testing done in this study will be performed either on bacterial isolates stored in the microbiology laboratory at the Diagnostic and Scientific Center in Calgary, or on up to one milliliter of residual urine sample submitted to the diagnostic laboratory with a request for urine culture and sensitivity. All urine cultures will be performed and reported in accordance with standards laboratory protocols. Research testing will only be done on residual sample once patient samples are processed or reported on for clinical purposes.

During the first phase of the study, metabolic biomarkers for uropathogens will be identified using mass spectrometry on sub-cultures of frozen isolates from the diagnostic microbiology laboratory. This will include at least 50 isolates each of uropathogens consisting of but not limited to Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterobacter species, Proteus mirabilis, Citrobacter species, Staphylococcus aureus, Staphylococcus saprophyticus, Pseudomonas aeruginosa, Enterococcus species, and Candida species. Biomarkers that are present in greater than 95% of the isolates will subsequently be using the analysis of 2000 negative, and 2000 positive urine cultures. Compounds that are subsequently identified as high yield will be selected for carbon 13 labeling to service standards.

In phase II of the study, following the development of a biomarker enrichment device at the CMRF, a performance urinalysis of the device will be conducted using residual urine sample from 1000 negative and 2000 positive urine specimens as outlined above. The performance of the new device will be evaluated relative to standard cultures and urine liquid chromatography-mass spectrometry.

Following the creation of a sensitive and specific assay, a prospective study will be carried out at the diagnostic microbiology laboratory. 3000 sample submitted for urine culture will be process in parallel with the new device and standard microbiology procedures. Sensitivity, specificity and predictive value for each analyte compared to standard culture will be determined in this portion of the study. Cost calculations and performance characteristics including turnaround time of the new assay will be compared to that in the standard laboratory procedure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bacterial Urinary Tract Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

UTI Positive

In phase I of the study testing residual urine samples the aim is to include at least 50 positive samples from each bacterial species known to be commonly associated with urinary tract infections. We selected 2000 positive urines to enable capturing enough of these organisms in the development process.

For phase II of the study, the same number of positive samples in order to include all common species causing urinary tract infection. The number of negative samples included is reduced to 1000.

Phase 3 - approximately one third of all urine sample submitted will be positive for a uropathogen. Sample size of 3000 we expect 1000 these to be culture positive. We expect most uropathogens occurring at a frequency of 5% or more will be included with sufficient numbers in the validation process.

No interventions assigned to this group

UTI Negative Control

2000 negative urine samples are being run as controlled to ensure the false positivity rate is low.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who have not submitted urine samples will not be included as the samples are required for both standard testing and research. This would include patients who are being treated empirically by physicians.